Drugs / 4-CNAB
4-CNAB
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00982254 Background | Oct → Nov 2001 | type 2 diabetes mellitus | Profil Institute for Metabolic Research GmbH | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-CNAB | “oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule)” NCT00982254 ↗ |
| Known as | Acide salclobuzique | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107776 ↗ |
| Known as | Acido salclobuzico | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107776 ↗ |
| Known as | SALCLOBUZATE SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107776 ↗ |
| Modality | Small molecule | — CHEMBL2107776 ↗ |
| Route | Oral | “oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule)” NCT00982254 ↗ |